Literature DB >> 12520464

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy.

Dietmar W Siemann1, Wenyin Shi.   

Abstract

It has been well established that the vascularization of solid tumors is a prerequisite if a clinically relevant size is to be reached. For progressive tumor growth, the vessel network must continuously expand to satisfy the neoplastic cells' nutritional needs and waste product removal requirements. This utter reliance of the tumor on its vasculature provides a logical target for new approaches to cancer therapy. Indeed, there currently exists a great deal of enthusiasm for the development of interventions that compromise the growth and/or function of the tumor neovasculature. Two primary directions are being pursued. Inhibitors of angiogenesis seek to interrupt the angiogenic process to prevent new vessel formation. Antivascular approaches aim to cause direct damage to the tumor endothelium and thus lead to extensive secondary neoplastic cell death. The application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12520464     DOI: 10.1053/srao.2003.50005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  8 in total

1.  Efficacy and safety of bevacizumab for the treatment of glioblastoma.

Authors:  Zhiyun Yu; Gang Zhao; Zhonghua Zhang; Yunqian Li; Yong Chen; Nan Wang; Zhongying Zhao; Guifang Xie
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

2.  Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.

Authors:  Lin Zhang; Feng-Yong Liu; Jin-Xin Fu; Feng Duan; Qing-Sheng Fan; Mao-Qiang Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice.

Authors:  Ai-Qing Zheng; Xian-Rang Song; Jin-Ming Yu; Ling Wei; Xing-Wu Wang
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

Review 4.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

Review 5.  Targeted radiotherapy with gold nanoparticles: current status and future perspectives.

Authors:  Wilfred Ngwa; Rajiv Kumar; Srinivas Sridhar; Houari Korideck; Piotr Zygmanski; Robert A Cormack; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nanomedicine (Lond)       Date:  2014-05       Impact factor: 5.307

Review 6.  Vascular targeted therapies in oncology.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Cell Tissue Res       Date:  2008-08-28       Impact factor: 5.249

7.  Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Authors:  Gazanfar Rahmathulla; Elizabeth J Hovey; Neda Hashemi-Sadraei; Manmeet S Ahluwalia
Journal:  Onco Targets Ther       Date:  2013-04-15       Impact factor: 4.147

8.  Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

Authors:  Hanna T Sjoberg; Yiannis Philippou; Anette L Magnussen; Iain D C Tullis; Esther Bridges; Andrea Chatrian; Joel Lefebvre; Ka Ho Tam; Emma A Murphy; Jens Rittscher; Dina Preise; Lilach Agemy; Tamar Yechezkel; Sean C Smart; Paul Kinchesh; Stuart Gilchrist; Danny P Allen; David A Scheiblin; Stephen J Lockett; David A Wink; Alastair D Lamb; Ian G Mills; Adrian Harris; Ruth J Muschel; Boris Vojnovic; Avigdor Scherz; Freddie C Hamdy; Richard J Bryant
Journal:  Br J Cancer       Date:  2021-06-21       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.